Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve

Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve.

The objective is to evaluate the influence of chemotherapy, either for auto-immune disease, either for carcinologic disease, on clinical and biological markers of ovarian reserve, for young patients, with normal reproductive functions.

The study will enrol patients between 18 and 35 years, treated with neoadjuvant or adjuvant chemotherapy for systemic lupus erythematosus (Group 1), breast cancer (Group 2) or Hodgkin disease (Group 3)to evaluate the clinical and biological markers of ovarian reserve. The follow-up will last 24 months for each patients with a visit before treatment, and at 3 months, 6 months, one year and two years after treatment.

During this period, we will collect pre and post treatment clinical data,and biological data and ultrasonographic data such as antral follicle count which is a marker of ovarian follicle reserve.These data were not observed in current practice.

Inclusion Criteria:

• Women volunteers treated by chemotherapy,
• ≥ 18 and ≤ 35 years old
• Regular menstrual cyclicity, between 25 and 35 days
• Social security affiliation
• Signed informed consent

Exclusion Criteria:

• Women < 18 and > 35 years old
• Pregnancy
• Emergent treatment necessity
• No social security affiliation
• Virgin patients